Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
visugromab (CTL-002)
i
Other names:
CTL-002
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
CatalYm
Drug class:
GDF15 inhibitor
Related drugs:
‹
AZD8853 (0)
NGM120 (0)
PF-06946860 (0)
AZD8853 (0)
NGM120 (0)
PF-06946860 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 expression
Bladder Cancer
PD-L1 expression
Bladder Cancer
nivolumab + CTL-002
Sensitive: C3 – Early Trials
nivolumab + CTL-002
Sensitive
:
C3
nivolumab + CTL-002
Sensitive: C3 – Early Trials
nivolumab + CTL-002
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.